First United Bank & Trust Has $648,000 Position in Zoetis Inc. (NYSE:ZTS)

First United Bank & Trust lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 12.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 3,935 shares of the company’s stock after selling 560 shares during the period. First United Bank & Trust’s holdings in Zoetis were worth $648,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ZTS. Rakuten Securities Inc. lifted its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC bought a new position in Zoetis in the 4th quarter worth $30,000. Murphy & Mullick Capital Management Corp bought a new position in Zoetis in the 4th quarter worth $44,000. Asset Planning Inc bought a new position in Zoetis in the 4th quarter worth $58,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in Zoetis in the 4th quarter worth $59,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS opened at $166.31 on Thursday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market cap of $74.04 billion, a PE ratio of 30.40, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company’s 50-day moving average price is $157.87 and its two-hundred day moving average price is $164.16. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Zoetis’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.38 earnings per share. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.20%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis’s payout ratio is presently 35.91%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president now owns 15,129 shares of the company’s stock, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ZTS shares. Piper Sandler lifted their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Monday, May 12th. UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Morgan Stanley dropped their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.